QA is conducting an audit on a study for ophthalmology which is ready for lock. Inconsistencies are found between the database and the source. Of the identified fields containing potential data errors, which fields are considered critical for this particular study?
Correct Answer: B
In an ophthalmology clinical study, data criticality is determined by how directly a data element affects safety evaluation, efficacy assessment, and regulatory decision-making. According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Validation and Cleaning), critical data fields are those that: Have a direct impact on the primary and secondary endpoints, or Are essential for safety interpretation and adverse event causality assessment. Among the listed options, Concomitant Medications (Option B) are considered critical data for ophthalmology studies. This is because many ocular treatments and investigational products can interact with systemic or topical medications, potentially affecting ocular response, intraocular pressure, corneal healing, or visual function outcomes. Any inconsistency in concomitant medication data could directly influence safety conclusions or efficacy interpretations. Other options, while important, are less critical for this study type: Subject Identifier (A) is essential for data traceability and audit purposes but is not directly related to safety or efficacy outcomes. Weight (C) may be relevant in dose-dependent drug trials but is rarely a pivotal variable in ophthalmology, where local administration (eye drops, intraocular injections) is common. Medical History (D) provides contextual background but does not have the same immediate impact on endpoint analysis as current concomitant treatments that can confound the therapeutic effect or cause ocular adverse events. Per GCDMP and ICH E6 (R2) GCP guidelines, data validation plans must define critical data fields during study setup, reflecting therapeutic area-specific priorities. For ophthalmology, concomitant medications, ocular assessments (visual acuity, intraocular pressure, retinal thickness, etc.), and adverse events are typically designated as critical fields requiring heightened validation, source verification, and reconciliation accuracy before database lock. Thus, when QA identifies discrepancies between the CRF and source, the Concomitant Medications field (Option B) is the most critical to address immediately to ensure clinical and regulatory data integrity. Reference (CCDM-Verified Sources): Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.4 - Critical Data Fields and Data Validation Prioritization ICH E6 (R2) Good Clinical Practice, Section 5.18 - Monitoring and Source Data Verification FDA Guidance for Industry: Oversight of Clinical Investigations - A Risk-Based Approach to Monitoring, Section 5.3 - Identification of Critical Data and Processes SCDM GCDMP Chapter: Data Quality Assurance and Control - Therapeutic Area-Specific Data Criticality Examples (Ophthalmology Studies)
Question 42
Data from two sites are combined. One site coded gender as 1 and 2 (for Male and Female, respectively) while the other stored the data as M and F. Which term best describes the mapping?
Correct Answer: D
When combining data from two datasets where one uses numeric codes (1 = Male, 2 = Female) and another uses text codes (M, F), each unique value in one dataset corresponds exactly to one unique value in the other. This relationship is a one-to-one mapping, where each element in one dataset maps directly to a single corresponding element in the other. 1 → M 2 → F Such mappings ensure consistent data harmonization during data integration and standardization phases, as outlined in the GCDMP (Chapter: Database Design and Integration). Many-to-one (C) mapping would occur if multiple values (e.g., "Male," "M," "Man") mapped to a single standardized value, which isn't the case here. Thus, the mapping is one-to-one, ensuring precise correspondence between both representations of gender data. Reference (CCDM-Verified Sources): SCDM GCDMP, Chapter: Database Design and Build, Section 5.4 - Data Mapping and Harmonization CDISC SDTM Implementation Guide, Section 5.2 - Controlled Terminology and Mapping Rules ICH E6(R2) GCP, Section 5.5.3 - Data Integrity and Integration Principles
Question 43
Which competency is necessary for EDC system use in a study using the medical record as the source?
Correct Answer: D
In studies where the medical record serves as the source document, the Electronic Data Capture (EDC) system users (typically study coordinators or site personnel) must have appropriate training on how to access and log into the medical record system. This competency ensures that data abstracted from the electronic medical record (EMR) are complete, accurate, and verifiable in compliance with Good Clinical Practice (GCP) and Good Clinical Data Management Practices (GCDMP). According to the GCDMP (Chapter: EDC Systems and Data Capture) and ICH E6(R2), all personnel involved in data entry and verification must be trained in both the EDC and the primary source systems (e.g., EMR). This ensures that the integrity of data flow-from source to EDC-is maintained, and that personnel understand system access controls, audit trails, and proper documentation of source verification. While resolving discrepant data (C) and screening subjects (A) are part of study operations, the competency directly related to EDC system use in EMR-based studies is the ability to properly log into and navigate the medical records system to extract source data. Reference (CCDM-Verified Sources): SCDM GCDMP, Chapter: Electronic Data Capture (EDC), Section 5.1 - Source Data and System Access Requirements ICH E6(R2) Good Clinical Practice, Section 4.9 - Source Documents and Data Handling FDA Guidance: Use of Electronic Health Record Data in Clinical Investigations, Section 3 - Investigator Responsibilities
Question 44
Which of the following actions is particularly important in merging data from different trials?
Correct Answer: D
When merging data from different clinical trials, the use of a common adverse event (AE) dictionary (such as MedDRA or WHO Drug) is essential to ensure consistency and comparability across datasets. According to the GCDMP (Chapter: Standards and Data Mapping) and CDISC SDTM Implementation Guide, data integration across studies requires standardized terminology for adverse events, medications, and clinical outcomes. Using the same AE dictionary ensures that similar terms are coded consistently, allowing accurate cross-study analysis, pooled summaries, and safety reporting. A shared software platform (option A) is not necessary if data are mapped to standard formats (e.g., CDISC SDTM). Patient population similarity (option B) affects interpretation but not technical data merging. Study design differences (option C) may influence statistical analysis but not data integration mechanics. Therefore, Option D - Use of a common adverse event dictionary - is the correct and most critical action for consistent multi-study data integration. Reference (CCDM-Verified Sources): SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Standards and Data Mapping, Section 5.1 - Use of Standardized Coding Dictionaries CDISC SDTM Implementation Guide, Section 4.3 - Controlled Terminology and Cross-Study Integration ICH E3 and E2B - Clinical Data Standards and Safety Coding Requirements
Question 45
A group of researchers is planning an investigator-initiated study. Assuming that SOPs are not available, which is the best approach for documentation of data management in the planned study?
Correct Answer: C
In the context of an investigator-initiated trial (IIT) where Standard Operating Procedures (SOPs) are not available, the most appropriate and compliant approach is to develop a Data Management Plan (DMP) template and then create a study-specific DMP based on that template (Option C). According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Management Planning and Study Start-up), the DMP is the central document that defines all processes, responsibilities, systems, and quality controls related to data collection, processing, validation, and database management throughout the clinical study. The DMP serves as a formal framework for ensuring data integrity, traceability, and regulatory compliance, especially in the absence of established institutional SOPs. While SOPs provide organizational-level standards, the DMP provides study-specific operational detail. In an investigator-initiated setting, researchers often lack institutional data management infrastructure, so the DMP must substitute for SOP guidance by detailing: Data entry and validation procedures Query management and resolution processes CRF design and data flow specifications Database design, backup, and security Responsibilities of study personnel (investigator, data manager, statistician) Quality control and audit trail practices Option A ("Data handling should be documented in a DMP") is correct in principle but incomplete-without a DMP template, there is no standardized format or consistency across studies. Option B (developing full SOPs) is not practical for a single IIT; SOPs are organizational-level documents requiring longer development and approval cycles. Option D (briefly describing data management in the protocol) is insufficient, as the protocol should reference data management activities but not serve as the operational manual for them. Therefore, Option C provides the most comprehensive, regulatory-compliant, and practical solution-ensuring structured documentation of all data management activities while maintaining flexibility for investigator-led research. Reference (CCDM-Verified Sources): Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 5.2 - Data Management Plan (DMP) Development and Maintenance ICH E6 (R2) Good Clinical Practice, Section 5.1 - Quality Management and Documentation Requirements FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 4 - Data Management and Documentation Practices SCDM GCDMP, Chapter: Project Management in Data Management - Study-Specific Documentation and Planning in Investigator-Initiated Trials
